Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - KING PHARMACEUTICALS INC | g21874e10vk.htm |
| EX-31.2 - EX-31.2 - KING PHARMACEUTICALS INC | g21874exv31w2.htm |
| EX-32.2 - EX-32.2 - KING PHARMACEUTICALS INC | g21874exv32w2.htm |
| EX-32.1 - EX-32.1 - KING PHARMACEUTICALS INC | g21874exv32w1.htm |
| EX-31.1 - EX-31.1 - KING PHARMACEUTICALS INC | g21874exv31w1.htm |
| EX-21.1 - EX-21.1 - KING PHARMACEUTICALS INC | g21874exv21w1.htm |
| EX-10.65 - EX-10.65 - KING PHARMACEUTICALS INC | g21874exv10w65.htm |
| EX-10.64 - EX-10.64 - KING PHARMACEUTICALS INC | g21874exv10w64.htm |
Exhibit 23.1
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the
Registration Statements on
Form S-8
(Nos.
333-70203,
333-73053,
333-45276,
333-45284,
333-126939,
and
333-128126)
and in the Registration Statement on
Form S-3
(No. 333-135285)
of King Pharmaceuticals, Inc. of our report dated
February 25, 2010 relating to the financial statements,
financial statement schedule and the effectiveness of internal
control over financial reporting, which appears in this
Form 10-K.
/s/
PricewaterhouseCoopers LLP
Charlotte, North Carolina
February 25, 2010